Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders

Inclusion Criteria: Subjects must meet all of the following criteria： * According to the World Health Organization (WHO) Classification of Haematopoietic and Lymphoid Tissue Tumours (2022), patients with relapsed/refractory plasma cell disorders that have received adequate treatment and lack effective therapeutic options, including: multiple myeloma, plasma cell leukemia, extramedullary plasmacytoma, solitary plasmacytoma, or primary amyloidosis.i) Relapsed: Disease progression occurs after one or more prior treatments, requiring salvage therapy, and does not meet the criteria for refractory disease.ii) Refractory: No response to initial treatment regimen or salvage therapy, or disease progression within 60 days after treatment. No response is defined as failure to achieve minimal response (MR) or disease progression during treatment. * The subject's predicted survival time is not less than three months. * Tumor cells confirmed to be GPRC5D positive by Flow Cytometry (FCM) or Immunohistochemistry. * The subject failed autologous and allogeneic hematopoietic stem cell transplantation. * Age 14-75 years (inclusive), both genders eligible. * ECOG performance status ≤ 2. * HGB≥70g/L(transfusion permitted). * The functions of vital organs need to meet the following conditions: ①Creatinine ≤ 2.5 × ULN or Cockcroft-Gault creatinine clearance \> 50 ml/min (excluding decreased serum creatinine clearance due to lymphoma mass compression), Combination with hemodialysis treatment is pe…